A shot against forgetfulness: How the shingles vaccine may shield the ageing brain
A large-scale study of over 1.5 million US Medicare beneficiaries aged 65 and older has found that receiving the two-dose recombinant zoster vaccine (RZV) is associated with a significantly lower risk of developing new-onset dementia, including Alzheimer’s disease and vascular dementia. The analysis, which matched vaccinated individuals to unvaccinated controls by age, sex, and race, revealed that those who received RZV had a 33% lower incidence of dementia during the first three years of follow-up, with the protective effect persisting beyond that period.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
